Brief: Protara Therapeutics Says Clinical Success Achieved With One Or Two Doses Of TARA-002 In 88% Of Patients

Protara Therapeutics

19/11/2025 13:45

Nov 19 (Reuters) - Protara Therapeutics Inc TARA.O:

PROTARA THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS DEMONSTRATING ROBUST RESPONSES IN THE ONGOING PHASE 2 STARBORN-1 TRIAL OF TARA-002 IN PEDIATRIC PATIENTS WITH LYMPHATIC MALFORMATIONS

PROTARA THERAPEUTICS INC: TARA-002 DEMONSTRATED FAVORABLE SAFETY AND TOLERABILITY PROFILE WITH NO SERIOUS ADVERSE EVENTS REPORTED

PROTARA THERAPEUTICS INC: CLINICAL SUCCESS ACHIEVED WITH ONE OR TWO DOSES OF TARA-002 IN 88% OF PATIENTS

PROTARA THERAPEUTICS - ONE PATIENT DISCONTINUED TREATMENT DUE TO A GRADE 2 AE OF FATIGUE

PROTARA THERAPEUTICS: MAJORITY OF ADVERSE EVENTS WERE MILD TO MODERATE, WITH NO SERIOUS AES REPORTED

Source text: ID:nGNXbj1hlN

Further company coverage: TARA.O

 ((Reuters.Briefs@thomsonreuters.com;))